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It is perhaps impossible not to get excited with the results of
FAME II trial which were presented at euro pcr recently. Ever
since the results of COURAGE trial were published, per-
forming PCI in symptomatic but stable CAD patients was
questioned, as the COURAGE trial did not show benefit of PCI
with optimal medical therapy over medical therapy alone. Of
course there were serious questions with the way the
COURAGE trial was conducted and its results. There were
considerable number of patients who crossed over to PCI
arm from the medical therapy group. Bare metal stents were
used in a large percentage of PCI arm of the study. The relief
of angina was significantly better in those who underwent
angioplasty. Notwithstanding these points a doubt lingered
in the mind of interventional cardiologist while performing
angioplasty in a stable patient “Am I really benefiting this
patient?”. COURAGE became a talking point for all those
arm chair cardiologists although their numbers are fast
dwindling.
Now for the first time we have the well executed FAME II
trial among stable patients of CAD using FFR to demonstrate
hemodynamic significance and then randomizing them to PCI
with medical therapy vs medical therapy alone. As shown in
FAME I trial, FFR-guided PCI reduced the risk of death, MI, or
repeat revascularization by 30% and death or MI by 35%,
compared with the current practice of using angiography to
guide decision making.
In the FAME II trial presented at EURO PCR recently,
subjects were slated for DES implantation in up to 3 vessels at
the time of enrollment. Based on their FFR results, patients
were stratified to different treatment strategies:
 Those with FFR >0.80 received OMT alone, with half
randomly assigned to follow-up in a registry (n ¼ 131)
 Those who had at least 1 stenosis with FFR 0.80, indicating
hemodynamic significance, entered into a randomized
comparison of OMT with (n ¼ 352) or without PCI (n ¼ 339)Table 1 e FAME II: preliminary results in the randomized coho
OMT alone (n ¼ 339) OMT þ
Urgent revascularization 6.0%
Any revascularization 12.1%As of November 2011, when the DSMB made its recom-
mendation to discontinue the trial, a total of 965 patients had
enrolled. Demographic factors and disease history were
similar between the randomized and registry patients, as was
clinical presentation. But within the randomized cohort, the
need for urgent or any revascularization was higher at 1 year
in patients assigned to OMT alone compared to OMT plus PCI
(Table 1), showing the value of FFR in identifying patients in
need of revascularization.
Importantly, outcomes were equivalent between the
registry patientsdwho were given OMT alone after being
cleared of having hemodynamically significant lesionsdand
those randomized to OMT plus PCI (P ¼ 0.71 for urgent and
P ¼ 0.54 for any revascularization).
Putting it differently, for patients with one or more signif-
icant lesions there was a 7.6 times greater risk of hospital
readmission with revascularization if they received OMT
alone. Further, there was an 11.2 times greater risk of the
need of unplanned hospital readmission with urgent
revascularization.
The final report on the trial’s primary endpoint, the
composite of all-cause death, MI, or unplanned hospitaliza-
tion with urgent revascularization has not been presented.
Thus now we have very important data that demon-
strates benefit of PCI coupled with medical therapy in
stable CAD patients provided they pass the FFR test. Of
course the final and long term (up to 5 years) results are
still awaited.
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PCI (n ¼ 352) HR (95% CI) Log-rank P value
0.6% 11.2 (2.62e47.9) <0.0001
1.7% 7.63 (3.24e18.0) <0.0001
